As the D Day for FDA approval of Mipomersen is drawing nearer, the ISIS SP should move up as I've previously mentioned. Once approved, the $1.5b milestone figure would be the catalyst for the SP to move above $16. All the ISIS pipeline drugs (including 3 from ANP) will be on the spotlight of big Pharmas.
T/O was mentioned as a possibility at the time of the Mipomersen deal in 2008 was announced.
ANP should benefit from the elevated status of Antisense drugs when that happens.
Just for comparison of how undervalued ANP is: The current MC of ISIS is $830m with 27 drugs in the pipeline. Including 3 from ANP. If we divide equally (assuming avg value of Phase 1 - 3 drugs) ANP drugs are value at $92m or 9.2cps of ANP. At 2cps currently, it is way undervalued.
GLTA and hope for great start of 2012.
ANP Price at posting:
20.0¢ Sentiment: Buy Disclosure: Held
